Strongbridge Biopharma plc (SBBP) to Post FY2017 Earnings of ($2.84) Per Share, Cantor Fitzgerald Forecasts
Strongbridge Biopharma plc (NASDAQ:SBBP) – Cantor Fitzgerald issued their FY2017 EPS estimates for shares of Strongbridge Biopharma in a research note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros expects that the biotechnology company will post earnings per share of ($2.84) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Strongbridge Biopharma’s FY2018 earnings at ($1.23) EPS.
A number of other research firms have also issued reports on SBBP. Zacks Investment Research lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $12.25.
Hedge funds and other institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth about $114,000. Rhumbline Advisers acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $331,000. 57.53% of the stock is currently owned by institutional investors and hedge funds.
About Strongbridge Biopharma
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.